TITLE

Development and validation of a sensitive and selective method using GC/MS-MS for quantification of 5-fluorouracil in hospital wastewater

AUTHOR(S)
Mullot, Jean-Ulrich; Karolak, Sara; Fontova, Anne; Huart, Bruno; Levi, Yves
PUB. DATE
August 2009
SOURCE
Analytical & Bioanalytical Chemistry;Aug2009, Vol. 394 Issue 8, p2203
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Pollution of the environment by pharmaceuticals is a subject of growing scientific and societal concern. However, few quantitative data have been reported concerning hospital wastewater contamination. Among the different molecules used at hospital, antineoplastic drugs appear to be of special interest, and 5-fluorouracil (5-FU) can be considered as a key compound of this therapeutic class. To monitor this pharmaceutical in hospital wastewater, a highly specific and selective method was developed using gas chromatography tandem mass spectrometry after solid-phase extraction. This sensitive method (limit of quantification = 40 ng L−1) was then applied to assess sewage contamination of a middle-size hospital with oncology service located in Paris, France. Native 5-FU was detectable in 12 of the 14 analysed samples. In positive samples, concentration range was measured from 0.09 to 4.0 μg L−1. Finally, a predicting model for the hospital wastewater concentrations is presented, and results of this model are discussed.
ACCESSION #
43467494

 

Related Articles

  • Fluorouracil.  // Reactions Weekly;Oct2015, Vol. 1571 Issue 1, p106 

    The article presents case reports of four patients who developed hyperammonaemia during fluorouracil-containing chemotherapy for large intestinal cancers. One patient underwent laparoscopic sigmoid colectomy, another one was diagnosed with metastatic ascending colon cancer and underwent...

  • Stability of commercial solutions of 5-fluorouracil for continuous infusion in an ambulatory pump. Fournet, Alexandra; Gilard, Véronique; Malet-Martino, Myriam; Martino, Robert; Canal, Pierre; De Forni, Marcel // Cancer Chemotherapy & Pharmacology;Dec2000, Vol. 46 Issue 6, p501 

    Purpose: The stability of 5-fluorouracil (FU) Roche solutions in a portable infusion pump under prolonged “in-use” conditions (32 °C, in the dark) was studied, especially with respect to the formation of the cardiotoxic compounds fluoroacetaldehyde (Facet) and fluoromalonic acid...

  • Fluorouracil Topical.  // AHFS Consumer Medication Information;Apr2018, p1 

    Fluorouracil cream and topical solution are used to treat actinic or solar keratoses (scaly or crusted lesions [skin areas] caused by years of too much exposure to sunlight). Fluorouracil cream and topical solution are also used to treat a type of skin cancer called superficial basal cell...

  • Actinic keratosis and capecitabine therapy. Higa, Gerald M.; Kovach, Rodney F.; Abraham, Jame // Journal of Oncology Pharmacy Practice;Dec2005, Vol. 11 Issue 4, p151 

    Topical application of 5-fluorouracil (5-FU) is one of the most effective clinical strategies available to treat actinic keratosis (AK). During treatment, an apparent toxic skin reaction occurs before dermal quiescence ensues. We report a case of a typical flare of AK in a woman treated with...

  • Capecitabine versus Bolus Fluorouracil plus Leucovorin (Folinic Acid) as Adjuvant Chemotherapy for Patients with Dukesʼ C Colon Cancer: Economic Evaluation in an Italian NHS Setting. Di Costanzo, Francesco; Ravasio, Roberto; Sobrero, Alberto; Bertetto, Oscar; Vinante, Orazio; Luppi, Gabriele; Labianca, Roberto; Amadori, Dino; Barone, Carlo; Carlo Merlano, Marco; Longo, Flavia; Mansueto, Giovanni; Antonuzzo, Lorenzo; Gasperoni, Silvia // Clinical Drug Investigation;2008, Vol. 28 Issue 10, p645 

    BACKGROUND AND OBJECTIVE: In the recent X-ACT (Xeloda in Adjuvant Colon cancer Therapy) trial, oral capecitabine (Xeloda) demonstrated superior efficacy and an improved safety profile compared with infused fluorouracil + leucovorin (folinic acid) [FU+LV] in patients with DukesÂ’ C colorectal...

  • Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Van Cutsem, E.; Hoff, P. M.; Harper, P.; Bukowski, R. M.; Cunningham, D.; Dufour, P.; Graeven, U.; Lokich, J.; Madajewicz, S.; Maroun, J. A.; Marshall, J. L.; Mitchell, E. P.; Perez-Manga, G.; Rougier, P.; Schmiegel, W.; Schoelmerich, J.; Sobrero, A.; Schilsky, R. L. // British Journal of Cancer;3/22/2004, Vol. 90 Issue 6, p1190 

    This study evaluates the efficacy of capecitabine using data from a large, well-characterised population of patients with metastatic colorectal cancer (mCRC) treated in two identically designed phase III studies. A total of 1207 patients with previously untreated mCRC were randomised to either...

  • Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel. Hee Yi; Hee-Jung Cho; Soo-Min Cho; Dong-Goo Lee; El-Aty, A. M. Abd; So-Jeong Yoon; Gun-Won Bae; Kwang Nho; Bokyung Kim; Chi-Ho Lee; Jin-Suk Kim; Bartlett, Michael G.; Ho-Chul Shin // BMC Cancer;2010, Vol. 10, p211 

    Background: We have studied the in vitro and in vivo utility of polyethylene glycol (PEG)-hydrogels for the development of an anticancer drug 5-fluorouracil (5-FU) delivery system. Methods: A 5-FU-loaded PEG-hydrogel was implanted subcutaneously to evaluate the drug retention time and the...

  • Macroscopic and Microscopic Effects of GaAIAs Diode Laser and Dexamethasone Therapies on Oral Mucositis Induced by Fluorouracil in Rats. Lara, Renata Nemetala; da Silva^Guerra, Eliete Neves; de Melo, Nilce Santos // Oral Health & Preventive Dentistry;2007, Vol. 5 Issue 1, p63 

    Purpose: To present an animal model for mucositis induced by fluorouracil in rats, and test two therapeutic options, the GaAIAs laser and topical dexamethasone, analysing them with regard to the quality and quantity of tissue alterations and comparing them with the phases of mucositis. Materials...

  • THE COMPARISON STUDY OF 5 FLUOROURACIL VS. CRYOTHERPY IN THE TREATMENT OF THE BACKHAND RESISTANT COMMON WART. Asghariazar, Rahim; Herizchi Ghadim, Hamideh; Babaeinezhad, Shahla; Nobahari, Sina // Our Dermatology Online / Nasza Dermatologia Online;Jul2014, Vol. 5 Issue 3, p258 

    Introduction: Wart is a common disease which is caused by a group of viruses called Human Papilloma Virus. The most prevalent type of wart is common wart and the most prevalent site of involvement is hands. Complete recovery, no recurrency and effectiveness in all patients are not obtained by...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics